×

HK-listed Guangzhou Innogen signs over $1 billion licensing deal for diabetes drug

By Thomson Reuters Nov 19, 2026 | 4:46 AM

Nov 19 (Reuters) – Hong Kong-listed Guangzhou Innogen Pharmaceutical said on Thursday it signed a licence agreement worth more ​than $1 billion with Arcera Life Sciences ‌to commercialise its GLP-1 receptor agonist drugs used to treat patients with type 2 diabetes.

The deal will allow Abu Dhabi-based Arcera to obtain ‌regulatory ​approvals and commercialise the ⁠pharmaceutical product containing Efsubaglutide ⁠Alfa for human therapeutic use in selected countries in Africa, Latin America, the Middle East and Eastern Europe, Guangzhou ​Innogen said.

• The China-based pharmaceutical products developer said its unit, Hong Kong Innogen ⁠Pharmaceutical, entered into the ⁠licensing deal with Arcera

• Under ​the deal, Innogen could receive up to $38 ​million in upfront and near-term milestone payments, ‌plus sales milestones and double-digit royalties tied to annual net sales

• The board said the deal is in shareholders’ best ⁠interests, leveraging Arcera’s commercial network to accelerate the global expansion and value of Efsubaglutide Alfa

• ⁠Arcera Life ‌Sciences is a global pharmaceutical ⁠and biotechnology firm with operations ​spanning ‌Africa, Europe, and parts of ​Latin America

• ⁠The deal comes as global drugmakers race to secure next-generation diabetes and obesity treatments offering greater convenience, tolerability and efficacy

(Reporting by Aamir Shaik Khalid in Bengaluru; Editing by ​Janane Venkatraman)